Anteris technologies announces first patients treated in duravr® thv global pivotal trial (the “paradigm trial”)

Minneapolis, united states and brisbane, australia, oct. 27, 2025 (globe newswire) -- anteris technologies global corp. (anteris or the company) (nasdaq: avr, asx: avr) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the duravr® transcatheter heart valve (thv) global pivotal trial for patients with severe calcific aortic stenosis (the “paradigm trial”). the procedures were performed by prof.
AVR Ratings Summary
AVR Quant Ranking